Novartis
Q2 2022 Earnings Call
Jul 19, 2022, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good morning, and good afternoon, and welcome to the Novartis Q2 2022 results release conference call and live webcast. [Operator instructions] A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends. With that, I would like to hand it over to Mr. Smith Shah, global head of investor relations.
Please go ahead, sir.
Samir Shah -- Global Head of Investor Relations
Thank you very much. And thank you to all of you who've joined us today on this beautiful summer's day for Novartis' Quarter 2 results. Before we start, I'll just read you the safe harbor statement. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors.
These may cause the actual results to be materially different from any future results, performance, or achievements expressed, or implied by such statements. For a description of some of these factors, please refer to the company's Form 20-F and its most recent quarterly results on Form 6-K that, respectively, were filed with and furnished to the U.S. Securities and Exchange Commission. And with that, I'll hand the call to Vas.
Thank you.
Vas Narasimhan -- Chief Executive Officer
Thank you, Samir, and thanks, everyone, for joining today's conference call. We're pleased to go over the results. I have with me today, Harry Kirsch, our CFO; and Karen Hale, our chief legal officer. Moving to Slide 4, as you saw in the release earlier today, we delivered a solid Quarter 2 across each of our key value drivers: 5% growth across the entire company, as well as in innovative medicines in Sandoz, continuing our productivity agenda with solid core operating income growth across the business, as well as continued margin expansion in constant currencies; as well as an upgrade to our expected savings from our transformation program to now 1.5 billion.
The innovation milestones, notably, we continue to garner approvals for Scemblix, our new medicine for CML, including a positive CHMP opinion. And then lastly, three milestones within our ESG efforts. First, the $250 million R&D commitment as part of the Kigali Declaration for neglected tropical diseases. We've increased our commitment to clinical trial diversity over the next 10 years through our Beacon of Hope project.